表紙
市場調查報告書

過敏性反應:開發中產品分析

Anaphylaxis - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 360911
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
過敏性反應:開發中產品分析 Anaphylaxis - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 58 Pages
簡介

過敏性反應是一種嚴重的潛在危及性命之過敏反應。症狀包括頭暈,噁心,嘔吐或腹瀉,熱感,氣道收縮和舌頭和喉嚨腫脹。 危險因素包括過敏反應,過敏或哮喘和家族史的個人病史。 治療包括使用β-激動劑,抗組織胺藥和可的松。

本報告提供過敏性反應的治療藥開發情形相關調查分析,提供開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

過敏性反應概要

治療藥的開發

  • 開發中產品概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Adamis Pharmaceuticals Corp
  • MannKind Corp
  • Monosol Rx LLC

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12210IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Pipeline Review, H1 2020, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.

Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anaphylaxis - Overview
    • Anaphylaxis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Anaphylaxis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Anaphylaxis - Companies Involved in Therapeutics Development
    • Aquestive Therapeutics Inc
    • ARS Pharmaceuticals Inc
    • Bryn Pharma LLC
    • G2B Pharma Inc
    • Insys Therapeutics Inc
    • JDP Therapeutics Inc
    • MannKind Corp
    • Merck & Co Inc
    • Shenox Pharmaceuticals LLC
  • Anaphylaxis - Drug Profiles
    • epinephrine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epinephrine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epinephrine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epinephrine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epinephrine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • epinephrine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDP-207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SHX-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XL-499 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Anaphylaxis - Dormant Projects
  • Anaphylaxis - Product Development Milestones
    • Featured News & Press Releases
      • May 04, 2020: Neurelis announces that Intravail Licensee, ARS Pharmaceuticals intranasal epinephrine product, demonstrates bioequivalent exposure to epinephrine injectors
      • Apr 06, 2020: Bryn Pharma presents data demonstrating comparable pharmacokinetic and pharmacodynamic effects of intranasal Epinephrine to intramuscular Epinephrine in adults
      • Mar 02, 2020: ARS Pharmaceuticals to present new data from Neffy (ARS-1) studies at AAAAI 2020 annual meeting
      • Feb 06, 2020: Aquestive Therapeutics announces FDA confirmed 505(b)(2) pathway for AQST-108 (sublingual film formulation delivering systemic epinephrine) for anaphylaxis treatment
      • Nov 10, 2019: Bryn Pharma Research on Epinephrine Nasal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting
      • Oct 29, 2019: Bryn Pharma presents data demonstrating patient preference for bi-dose epinephrine nasal spray over EpiPen
      • Oct 10, 2019: Bryn Pharma completes dosing in pivotal clinical trial designed to support U.S. approval of Intranasal Epinephrine Spray
      • Sep 30, 2019: Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)
      • Jun 04, 2019: ARS Pharmaceuticals announces results from EPI-04 clinical study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis
      • Feb 25, 2019: INSYS Therapeutics presented poster of initial pharmacokinetic study of Epinephrine Nasal Spray for the emergency treatment of allergic reactions (Type I) including anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting
      • Feb 19, 2019: ARS Pharmaceuticals announces FDA Fast Track Designation for ARS-1 intranasal epinephrine spray
      • Dec 19, 2018: ARS Pharmaceuticals advances clinical program for intranasal epinephrine spray
      • Dec 17, 2018: INSYS Therapeutics provides update on Epinephrine nasal spray for anaphylaxis
      • Aug 30, 2018: FDA Grants INSYS Therapeutics Fast Track Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis
      • Jun 14, 2018: Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Anaphylaxis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, H1 2020
  • Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, H1 2020
  • Anaphylaxis - Pipeline by Bryn Pharma LLC, H1 2020
  • Anaphylaxis - Pipeline by G2B Pharma Inc, H1 2020
  • Anaphylaxis - Pipeline by Insys Therapeutics Inc, H1 2020
  • Anaphylaxis - Pipeline by JDP Therapeutics Inc, H1 2020
  • Anaphylaxis - Pipeline by MannKind Corp, H1 2020
  • Anaphylaxis - Pipeline by Merck & Co Inc, H1 2020
  • Anaphylaxis - Pipeline by Shenox Pharmaceuticals LLC, H1 2020
  • Anaphylaxis - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Anaphylaxis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020